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Somatostatin secretionPancreatic polypeptide (PP) is a major agonist for neuropeptide Y4 receptors (NPY4R). While NPY4R
has been identiﬁed in various tissues, the cells on which it is expressed and its function in those cells
has not been clearly delineated. Here we report that NPY4R is present in all somatostatin-containing
cells of tissues that we tested, including pancreatic islets, duodenum, hippocampus, and hypothal-
amus. Its agonism by PP decreases somatostatin secretion from human islets. Mouse embryonic
hippocampal (mHippo E18) cells expressed NPY4Rs and their activation by PP consistently
decreased somatostatin secretion. Furthermore, central injection of PP in mice induced c-Fos immu-
noreactivity in somatostatin-containing cells in the hippocampus compared with PBS-injected mice.
In sum, our results identify PP as a pivotal modulator of somatostatin secretion.
Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
Pancreatic polypeptide (PP), gut derived peptide YY (PYY) and
the neuronal derived peptide neuropeptide Y (NPY) belong to a
family of structurally related peptides which have functions in
both neural and endocrine signaling [1,2]. Relatively little is known
about the functional signiﬁcance of PP, a 36-amino acid peptide
secreted by PP (or F) cells of the islets of Langerhans in the pan-
creas and released into the circulation. PP is also expressed in
endocrine cells of both small and large intestine [3,4]. It shares
considerable homology with the peptide sequences of PYY and
NPY, and is reported to have effects on several gastrointestinal
functions such as gastric motility, gallbladder contraction, and
pancreatic exocrine secretion [5]. Previous studies have shown that
PP appears to be involved in regulating food intake and energy bal-
ance [6]. Transgenic mice overexpressing PP gained less weight
because of decreased food intake and this was accompanied by
decreased fat mass [7]. Peripheral administration of PP to geneti-
cally obese ob/ob mice induced a state of negative energy balance
because of decreased food intake and increased energy expendi-
ture [8]. In humans, intravenous infusions of PP reduced food
intake [9], and low circulating levels of PP have been observed inobese people [10–12]. PP secretion was thought to be primarily
under vagal control [13], although other factors have also been
shown to alter circulating PP concentrations [14]. Increasing
plasma concentrations are seen after the ingestion of food and
remain elevated for up to 6 h [1,2,15]. In type 2 diabetic subjects,
PP cells secrete excess PP and plasma PP levels are signiﬁcantly
elevated in the postprandial state, compared to non-diabetic
subjects [16].
The biological effects of the NPY family peptides are exerted
through the NPY receptor family, which consists of at least ﬁve dis-
tinct members (Y1, Y2, Y4, Y5, and Y6) [17]. As PP has the highest
afﬁnity for the NPY4 receptor (NPY4R), it is thought to be the major
endogenous ligand for this receptor [18]. PP dose-dependently
reduced food intake in fed and fasted mice, and this effect was
completely abolished in NPY4R-null mice, indicating that the effect
is entirely mediated by NPY4Rs [19]. NPY4R is a G protein-coupled
receptor and its activation by PP inhibits forskolin-stimulated
cAMP synthesis in several NPY4R-containing cell lines [18,20,21].
NPY4Rs are present in the peripheral organs, including the gastro-
intestinal tract, liver, pancreas, and heart [18,20,22–24]. Addition-
ally, signiﬁcant amounts of NPY4R mRNA and speciﬁc binding sites
have been found in key areas of the brain including hypothalamus
and hippocampus [20,23,24], underscoring the importance of the
receptor to food intake. Because circulating PP levels are highest
after eating, we investigated if PP, besides modulating food intake,
is involved in locally regulating secretion from any of the islet cell
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taining delta (d) cells in islets of Langerhans, but not the other islet
cell types. We then investigated if somatostatin-expressing cells in
other organs, such as in duodenum and brain, also express NPY4R.
2. Materials and methods
2.1. Materials and reagents
mHippo E18 cells were from CELLutions Biosystems Inc. The
somatostatin EIA kit was from Phoenix Pharmaceuticals, human
insulin ELISA from Mercodia, and pancreatic polypeptide (PP)
was from BACHEM. Human islets were provided by the NIDDK-
funded Integrated Islet Distribution Program (IIDP) at City of Hope.
Frozen brain sections (40 lm) were from a 10 year old male rhesus
macaque. Dr. Frederic B. Askin from the Department of Pathology
at The Johns Hopkins University School of Medicine provided
anonymous human tissues.
2.2. Cell culture and somatostatin and insulin secretion
mHippo E18 cells and insulin-secreting MIN6 cells were cul-
tured in DMEM (Invitrogen) with 10% fetal bovine serum (FBS),
25 mM glucose, and 1% penicillin/streptomycin and maintained
at 37 C with 5% CO2. Cells were seeded into 35 mm dishes, grown
to conﬂuency, washed 1X with PBS, and treated with 0.1 lM of PP
or PBS as vehicle in triplicate for 48 h. Media was collected and
somatostatin levels were measured using a somatostatin EIA kit.
For human islet experiments, we picked 100 size-matched islets
per tube in Krebs buffer followed by 30 min incubation at 37 C.
We pelleted the islets and treated with Krebs buffer containing
1 lM of PP or PBS. After 20 min incubation at 37 C, we collected
the supernatant and somatostatin levels were measured using a
somatostatin EIA kit and insulin was measured by ELISA according
to the manufacturers’ instructions. Total protein concentration was
measured by BSA assay (Pierce) for normalization.
2.3. Western blotting and densitometry
Cells and homogenized mouse liver were lysed in RIPA buffer
(25 mM HEPES, 134 mM NaCl, 1% NP-40, 0.1% SDS, 1 mM sodium
orthovanadate, 0.5% sodium deoxycholate, 100 mM NaF) supple-
mented with protease inhibitor cocktail set I and phosphatase
inhibitor cocktail set II (Calbiochem) for 20 min ice with occasional
vortexing, and then pelleted in a microcentrifuge at maximum
speed for 20 min to remove insoluble material. Following a BCA
protein assay, 50 lg of lysate was resolved on 4–12% Tris–glycine
gels (Invitrogen) and blotted onto polyvinylidene diﬂuoride (PVDF)
membranes using the iBlot (Invitrogen). The blots were blocked in
5% milk/TBS-T for 1 h at room temperature and probed with anti-
NPY4R (1:1000, Santa Cruz) or anti-GAPDH (1:500, Santa Cruz)
antibodies in blocking buffer overnight at 4 C. Membranes were
washed with TBS-T and the appropriate secondary antibody
(1:5000, GE Heathcare) was added in 5% milk/TBS-T for 1 h at room
temperature. Membranes were washed again with TBS-T and
developed using ECL Plus (GE Heathcare). Western blot images
were scanned, saved as Tiff ﬁles, inverted, and integrated density
was analyzed using ImageJ software (National Institutes of Health).
Values were normalized to GAPDH.
2.4. Transcranial stereotaxic injection of PP to the hippocampus
Two-month-old male B6C3F1/J mice were initially anesthetized
with 4% isoﬂurane and then maintained on 1.5% isoﬂurane anes-
thesia for the duration of the surgery. During stereotaxic surgeries,
mice were maintained on a heating pad to ensure constant bodytemperature. Mouse heads were secured in a stereotaxic apparatus
and a longitudinal midsagittal cut was made with a sterile scalpel
to expose the skull. Injections were performed through a small
hole in the skull drilled along the anterior-posterior and mediolat-
eral coordinates using a 1.0 mm drill head. Injections to the dorsal
hippocampus were performed at the following coordinates, repre-
senting distances in mm from skull bregma: anterior–posterior
2.1, mediolateral ±1.35 and dorsoventral 2.1. PP (1 lM) was
injected in a constant ﬂow of 0.2 ll/min followed by 3 min to allow
the ﬂuid to be absorbed by the tissue. PP was stereotaxically
injected into right side of the hippocampus. An equal volume of
PBS was injected into the left hippocampus to serve as a control.
Injections were performed using a CMA-400 automatic pump
pushing two Hamilton syringes simultaneously. The syringes were
connected via PE10 tubing to a 27 gauge needles. Following the
injections, the skin was sutured and mice were placed in a separate
cage. Exactly at 15, 30 and 60 min after PP injection, mice were
perfused with 4% paraformaldehyde and the brains were rapidly
dissected.
2.5. Immunostaining
Parafﬁn-embedded human islets and tissues were prepared as
previously described [25]. For frozen sections, tissues were rapidly
dissected, ﬁxed in 4% paraformaldehyde, immersed in 30% sucrose,
embedded in O.C.T compound (Tissue-Tek) before freezing, and
then sectioned at a thickness of 7 lm. After antigen unmasking
(BioGenex), the tissues were blocked with 5% BSA/PBS for 1 h at
room temperature and incubated overnight at 4 C with anti-
insulin (1:500; Millipore), anti-glucagon (1:1000; Sigma), anti-PP
(1:1000; Millipore), anti-NPY4R (1:100; Santa Cruz), anti-somato-
statin (1:200; Santa Cruz) and anti-c-Fos (1:100; Santa Cruz) anti-
bodies. After washing, tissues were incubated with the appropriate
secondary antibodies (1:500, Jackson ImmunoResearch) along with
TO-PRO-3 (1:5000, Molecular Probes), in some cases, for nuclear
staining. Slides were viewed using a LSM-710 confocal microscope
(Carl Zeiss MicroImaging).
2.6. Statistical analysis
Quantitative data are presented as the mean ± S.E.M.
Differences between mean values were compared statistically by
Student’s t-test. Comparisons were performed by using Graphpad
Prism (GraphPad Software). A P value of <0.05 was considered
statistically signiﬁcant.3. Results
3.1. NPY4R is expressed in somatostatin-containing cells
Somatostatin-containing cells are dispersed throughout the gut,
pancreas, and brain [26–28]. We ﬁrst looked for evidence of the
presence of NPY4Rs in both human and mouse islets. By immuno-
staining, NPY4Rs were colocalized with somatostatin-containing
cells (Fig. 1A), but were absent from PP (F), insulin-containing
(b), and glucagon-containing (a) cells in human islets (Fig. 1A
and B). Consistent with this result, NPY4Rs were only present in
somatostatin-containing cells in mouse islets (Fig. 1C and D). We
also conﬁrmed their presence in the somatostatin-containing cells
in both human and mouse duodena by immunostaining (Fig. 2A
and B).
As somatostatin is also found in neural tissues including hypo-
thalamus and hippocampus [29,30], we evaluated the presence of
NPY4R in somatostatin-containing cells in brain. NPY4Rs were
expressed in somatostatin-containing cells in the hippocampus
Fig. 1. The colocalization of NPY4R with somatostatin-containing cells in pancreatic islets. (A) Immunoﬂuorescent images showing that NPY4R (red) is colocalized with
somatostatin-containing cells (green), but not PP cells (blue), in human islets. (B) Immunoﬂuorescent images showing that NPY4R (red) is not colocalized with insulin (green)
or glucagon (blue) in human islets. (C) Immunoﬂuorescent images showing that NPY4R (red) is colocalized with somatostatin-containing cells (green) in mouse islets. (D)
Immunoﬂuorescent images showing that NPY4R (red) is not colocalized with insulin (green) or glucagon (blue) in mouse islets. Scale bar = 50 lm.
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B) and in the hippocampus of mouse brain (Fig. 3C).
3.2. PP inhibits somatostatin secretion
To investigate whether PP modulates somatostatin secretion,
we treated human islets with 1 lM PP and measured somatostatin
and insulin levels in the medium. PP treatment led to decreased
somatostatin secretion from human islets (Fig. 4A). Conversely
insulin secretion from human islets was signiﬁcantly increased
by PP (Fig. 4B), which is consistent with the fact that somatostatin
inhibits insulin release from pancreatic islets [31,32]. To further
conﬁrm that PP modulates somatostatin secretion in other somato-
statin-containing cells besides pancreatic d cells, we used mouse
embryonic hippocampal (mHippo E18) cells. Western blot analysisconﬁrmed that NPY4Rs are expressed in mouse liver, as expected,
and mHippo E18 cells, but lacking in MIN6 cells (Fig. 5A), as is true
of b cells in situ (Fig. 1). Consistent with the results in isolated
islets (Fig. 4A), somatostatin secretion from mHippo E18 cells
was signiﬁcantly decreased by 0.1 lM PP (Fig. 5B), conﬁrming
the inhibitory action of PP on somatostatin secretion in a
receptor-dependent manner.
3.3. PP activates somatostatin-containing cells in the hippocampus of
mouse
The evidence shown above is not a direct measure of neuronal
activation and does not directly show functionally active NPY4Rs.
To determine whether NPY4Rs are activated in somatostatin-
containing cells in vivo, we investigated the expression of the
Fig. 2. The colocalization of NPY4R with somatostatin-containing cells in duodenum. Immunoﬂuorescent images showing that NPY4R (red) colocalized with somatostatin
(green) in human (A) and mouse (B) duodena. TO-PRO-3 (blue) was used to stain nuclei. Scale bar = 50 lm.
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of mouse brain as early as 30 min after PP injection into the
hippocampus. No c-Fos immunoreactivity was seen in somato-
statin-containing cells in PBS-injected controls, while after PP
injection, c-Fos was easily visualized in those cells (Fig. 6).4. Discussion
Here we report the ﬁrst evidence that NPY4R is present in mam-
malian somatostatin-containing cells, including d cells in islets of
Langerhans. While we do not have isolated islets from a NPY4R
null mouse to provide direct evidence, it is likely that PP is activat-
ing NPY4R, leading to a decrease in somatostatin secretion. As
somatostatin-containing d cells are distributed widely throughout
the nervous system, particularly hippocampus and hypothalamus,
and in the gut [26–28,33], we tested those tissues for NPY4R
expression and found that NPY4Rs are expressed in all somato-
statin-containing cells that we tested. In pancreatic islets, NPY4Rs
are expressed only in d cells, and not in the other cell types (F, b,
and a cells). Such degree of speciﬁcity led us to examine its func-
tional signiﬁcance to islet physiology.
PP treatment led to increased insulin secretion from isolated
human islets, most likely because it decreased somatostatin secre-
tion, a known inhibitor of insulin secretion [31,32]. We therefore
present evidence for the functional signiﬁcance of increased PP
secretion within islets: it decreases somatostatin secretion that
acts as a brake on insulin secretion. Elevated PP levels in type 2 dia-
betes [16] likely represent a compensatory response in an effort to
restore normal blood glucose by decreasing somatostatin secretion
within islets.
Gut–islet interactions have been well studied because incretin
hormones (GIP, GLP-1) released from scattered enteroendocrinecells regulate glucose-mediated insulin secretion. We now show
the converse in an islet-gut interaction through PP regulation of
somatostatin-containing enteroendocrine cells. Somatostatin
inhibits release of a large number of gastrointestinal endocrine
hormones (CCK, secretin, gastrin, GIP, and GLP-1) but levels of all
of these actually increase in the circulation after eating [34–36].
Hence suppression of somatostatin postprandially in the gut is a
vital necessity. So gut–islet interactions via hormones are bidirec-
tional. Additionally, somatostatin is known to inhibit pancreatic
exocrine secretion, hepatic bile secretion, and gall bladder empty-
ing [34,37,38]. These three effects need to be disinhibited after eat-
ing; a role PP now seems to be responsible for via local inhibition of
somatostatin secretion.
Uncovering that PP, actively secreted after eating, may directly
activate somatostatin-containing neurons in the brain is very inter-
esting. We used c-Fos as a marker for neuronal activation by PP of
somatostatin-containing cells because it is rapidly increased by
many physiologic and pharmacologic stimuli in the central
nervous system. Although somatostatin-positive cells comprise a
relatively small subpopulation of hippocampal interneurons, they
are anatomically positioned to mediate a powerful inhibitory drive
on granule and pyramidal cell activity [39]. Nearly all somato-
statin-expressing neurons throughout the hippocampus colocalize
with GAD, and the vulnerability of these cells is thought to contrib-
ute to memory impairment in a variety of conditions, including
Alzheimer Disease [40] and animal models of age-related neurode-
generation [41]. Consistent with this proposal, recent evidence
indicates that somatostatin protein expression is dramatically
decreased in the hilus of the dentate gyrus in a rat model of
cognitive aging, selectively among aged individuals that display
deﬁcits in spatial memory dependent on the hippocampus [42].
Our data suggests that somatostatin-containing cells are dynami-
cally regulated in the hippocampus and are highly responsive to
Fig. 3. The colocalization of NPY4R with somatostatin-containing cells in brain. Immunoﬂuorescent images showing that NPY4R (red) colocalized with somatostatin (green)
in human (A) and monkey (B) hypothalamus and hippocampus and mouse (C) hippocampus. Scale bar = 50 lm.
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factor not previously appreciated. That somatostatin-expressing
neurons are uniquely activated by a speciﬁc islet hormone, PP,
demonstrates a direct peripheral to central connectivity previouslynot appreciated in this population of cells. It would be of interest to
investigate if pharmacological levels of PP might protect against
loss of somatostatin-containing cells in animal models of age-
related neurodegeneration.
Fig. 4. Effects of PP on somatostatin and insulin secretion in human islets. Levels of somatostatin (A) and insulin (B) secreted into the media from 100 size matched human
islets incubated with 1 lM PP or PBS for 20 min were analyzed and normalized to total protein concentration. Data are shown as the mean ± S.E.M. ⁄⁄P < 0.01.
Fig. 5. Effects of PP on somatostatin secretion in mouse embryonic hippocampal (mHippo E18) cells. (A) Western blot analysis of NPY4R expression in total lysates prepared
from mouse liver, mHippo E18 cells, and MIN6 cells. Mouse liver and MIN6 cells were used as a positive and negative control, respectively, for NPY4R. Signals on Western
blots were quantiﬁed by densitometry and shown in the bottom panel. (B) Somatostatin secretion from mHippo E18 cells incubated with 0.1 lM PP for 48 h. Data are shown
as the mean ± S.E.M. from three independent experiments. ⁄P < 0.05.
Fig. 6. c-Fos immunoreactivity in the hippocampus of PP-injected mice. Representative images showing somatostatin (green) and c-Fos (red) immunoreactivity in mouse
hippocampus 30 min after injection with PBS (top panel) or PP (bottom panel). TO-PRO-3 (blue) was used to stain nuclei. Scale bar = 50 lm.
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W. Kim et al. / FEBS Letters 588 (2014) 3233–3239 3239In summary, PP secretion is increased locally within islets after
eating. There, it suppresses somatostatin secretion and conse-
quently, a brake on insulin secretion is lifted. This allows the full
capability of b cells to respond to incretins and glucose and release
insulin as appropriate to the fed state. At the same time, PP secre-
tion into the circulation increases and it then inhibits somatostatin
secretin in the gut, again locally disinhibiting all the inhibitory
functions of somatostatin on hormone secretion and dynamic
gut–pancreatic–bile functions. Most intriguingly, PP activates
somatostatin-containing cells in the brain. The full signiﬁcance of
this awaits further investigation.
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